Skip to main content
Erschienen in: The European Journal of Health Economics 1/2016

08.04.2016 | Original Paper

Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe

verfasst von: Karine Chevreul, Morgane Michel, Karen Berg Brigham, Julio López-Bastida, Renata Linertová, Juan Oliva-Moreno, Pedro Serrano-Aguilar, Manuel Posada-de-la-Paz, Domenica Taruscio, Arrigo Schieppati, Georgi Iskrov, Márta Péntek, Johann Matthias Graf von der Schulenburg, Panos Kanavos, Ulf Persson, Giovani Fattore, BURQOL-RD Research Network

Erschienen in: The European Journal of Health Economics | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Our goal was to provide data on the economic burden and health-related quality of life (HRQOL) of patients with cystic fibrosis (CF) and their caregivers in Europe.

Methods

A cross-sectional study was carried out on adults and children with CF in eight European countries. Patients completed an anonymous questionnaire regarding their socio-demographic characteristics, use of healthcare services and presence of a caregiver. Costs were calculated with a bottom-up approach using unit costs from each participating country, and HRQOL was assessed using EQ-5D. The principal caregiver also answered a questionnaire on their characteristics, HRQOL and burden.

Results

A total of 905 patients with CF was included (399 adults and 506 children). The total average annual cost per patient varied from €21,144 in Bulgaria to €53,256 in Germany. Adults had higher direct healthcare costs than children, but children had much higher informal care costs (P < 0.0001). Total costs increased with patients’ level of dependence. In adults, mean utility fell between 0.640 and 0.870, and the visual analogue scale ranged from 46.0 to 69.7. There was no difference in caregiver HRQOL regardless of whether they cared for an adult or a child. However, caregivers who looked after a child had a significantly higher burden (P = 0.0013).

Conclusions

Our study highlights the burden of CF in terms of costs and decreased HRQOL for both patients and their caregivers throughout Europe.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Bradley, J.M., Blume, S.W., Balp, M.-M., Honeybourne, D., Elborn, J.S.: Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur. Respir. J. 41, 571–577 (2013)CrossRefPubMed Bradley, J.M., Blume, S.W., Balp, M.-M., Honeybourne, D., Elborn, J.S.: Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur. Respir. J. 41, 571–577 (2013)CrossRefPubMed
5.
Zurück zum Zitat Abbott, J., Hurley, M.A., Morton, A.M., Conway, S.P.: Longitudinal association between lung function and health-related quality of life in cystic fibrosis. Thorax 68, 149–154 (2013)CrossRefPubMed Abbott, J., Hurley, M.A., Morton, A.M., Conway, S.P.: Longitudinal association between lung function and health-related quality of life in cystic fibrosis. Thorax 68, 149–154 (2013)CrossRefPubMed
6.
Zurück zum Zitat Hegarty, M., Macdonald, J., Watter, P., Wilson, C.: Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev. 35, 462–468 (2009)CrossRefPubMed Hegarty, M., Macdonald, J., Watter, P., Wilson, C.: Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev. 35, 462–468 (2009)CrossRefPubMed
8.
Zurück zum Zitat Dewitt, E.M., Grussemeyer, C.A., Friedman, J.Y., Dinan, M.A., Lin, L., Schulman, K.A., Reed, S.D.: Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 15, 277–283 (2012)CrossRef Dewitt, E.M., Grussemeyer, C.A., Friedman, J.Y., Dinan, M.A., Lin, L., Schulman, K.A., Reed, S.D.: Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 15, 277–283 (2012)CrossRef
9.
Zurück zum Zitat Heimeshoff, M., Hollmeyer, H., Schreyögg, J., Tiemann, O., Staab, D.: Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. PharmacoEconomics. 30, 763–777 (2012)CrossRefPubMed Heimeshoff, M., Hollmeyer, H., Schreyögg, J., Tiemann, O., Staab, D.: Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. PharmacoEconomics. 30, 763–777 (2012)CrossRefPubMed
10.
Zurück zum Zitat Van Gool, K., Norman, R., Delatycki, M.B., Hall, J., Massie, J.: Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 16, 345–355 (2013)CrossRef Van Gool, K., Norman, R., Delatycki, M.B., Hall, J., Massie, J.: Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 16, 345–355 (2013)CrossRef
11.
Zurück zum Zitat Mahoney, F., Barthel, D.: Functional evaluation: the Barthel Index. Md. State Med. J. 14, 61–65 (1965)PubMed Mahoney, F., Barthel, D.: Functional evaluation: the Barthel Index. Md. State Med. J. 14, 61–65 (1965)PubMed
12.
Zurück zum Zitat Collin, C., Wade, D.T., Davies, S., Horne, V.: The Barthel ADL Index: a reliability study. Int. Disabil. Stud. 10, 61–63 (1988)CrossRefPubMed Collin, C., Wade, D.T., Davies, S., Horne, V.: The Barthel ADL Index: a reliability study. Int. Disabil. Stud. 10, 61–63 (1988)CrossRefPubMed
13.
Zurück zum Zitat Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can. J. Aging 19, 494–507 (2000) Hérbert, R., Bravo, G., Préville, M.: Reliability, validity, and reference values of the Zarit Burden Interview for assessing informal caregivers of community-dwelling older persons with dementia. Can. J. Aging 19, 494–507 (2000)
14.
Zurück zum Zitat Van den Berg, B., Brouwer, W.B.F., Koopmanschap, M.A.: Economic valuation of informal care. An overview of methods and applications. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care. 5, 36–45 (2004)CrossRef Van den Berg, B., Brouwer, W.B.F., Koopmanschap, M.A.: Economic valuation of informal care. An overview of methods and applications. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care. 5, 36–45 (2004)CrossRef
15.
Zurück zum Zitat McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–405 (2001)CrossRefPubMed McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int. J. Geriatr. Psychiatry 16, 400–405 (2001)CrossRefPubMed
16.
Zurück zum Zitat Hodgson, T., Meiners, M.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Memorial Fund Q./Health Soc. 60, 429–462 (1982) Hodgson, T., Meiners, M.: Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Memorial Fund Q./Health Soc. 60, 429–462 (1982)
17.
Zurück zum Zitat Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., Badia, X.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 20, 1727–1736 (2011)CrossRef Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., Badia, X.: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 20, 1727–1736 (2011)CrossRef
18.
Zurück zum Zitat Tarricone, R.: Cost-of-illness analysis. What room in health economics? Health Policy Amst. Neth. 77, 51–63 (2006)CrossRef Tarricone, R.: Cost-of-illness analysis. What room in health economics? Health Policy Amst. Neth. 77, 51–63 (2006)CrossRef
20.
Zurück zum Zitat Horvais, V., Touzet, S., François, S., Bourdy, S., Bellon, G., Colin, C., Durieu, I.: Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int. J. Technol. Assess. Health Care 22, 525–531 (2006)CrossRefPubMed Horvais, V., Touzet, S., François, S., Bourdy, S., Bellon, G., Colin, C., Durieu, I.: Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int. J. Technol. Assess. Health Care 22, 525–531 (2006)CrossRefPubMed
21.
Zurück zum Zitat Huot, L., Durieu, I., Bourdy, S., Ganne, C., Bellon, G., Colin, C., Touzet, S., REMU study: Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc. 7, 403–408 (2008)CrossRef Huot, L., Durieu, I., Bourdy, S., Ganne, C., Bellon, G., Colin, C., Touzet, S., REMU study: Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc. 7, 403–408 (2008)CrossRef
22.
Zurück zum Zitat Briesacher, B.A., Quittner, A.L., Fouayzi, H., Zhang, J., Swensen, A.: Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001–2007. Pediatr. Pulmonol. 46, 770–776 (2011)CrossRefPubMed Briesacher, B.A., Quittner, A.L., Fouayzi, H., Zhang, J., Swensen, A.: Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001–2007. Pediatr. Pulmonol. 46, 770–776 (2011)CrossRefPubMed
25.
Zurück zum Zitat Eidt-Koch, D., Wagner, T.O.F., Mittendorf, T., Graf von der Schulenburg, J.-M.: Outpatient medication costs of patients with cystic fibrosis in Germany. Appl. Health Econ. Health Policy 8, 111–118 (2010)CrossRefPubMed Eidt-Koch, D., Wagner, T.O.F., Mittendorf, T., Graf von der Schulenburg, J.-M.: Outpatient medication costs of patients with cystic fibrosis in Germany. Appl. Health Econ. Health Policy 8, 111–118 (2010)CrossRefPubMed
26.
Zurück zum Zitat Stolk, E.A., Busschbach, J.J., Vogels, T.: Performance of the EuroQol in children with imperforate anus. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 9, 29–38 (2000)CrossRef Stolk, E.A., Busschbach, J.J., Vogels, T.: Performance of the EuroQol in children with imperforate anus. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 9, 29–38 (2000)CrossRef
27.
Zurück zum Zitat Polinder, S., Meerding, W.J., Toet, H., Mulder, S., Essink-Bot, M.-L., van Beeck, E.F.: Prevalence and prognostic factors of disability after childhood injury. Pediatrics 116, e810–e817 (2005)CrossRefPubMed Polinder, S., Meerding, W.J., Toet, H., Mulder, S., Essink-Bot, M.-L., van Beeck, E.F.: Prevalence and prognostic factors of disability after childhood injury. Pediatrics 116, e810–e817 (2005)CrossRefPubMed
28.
Zurück zum Zitat Willems, D.C.M., Joore, M.A., Nieman, F.H.M., Severens, J.L., Wouters, E.F.M., Hendriks, J.J.E.: Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. Int. J. Technol. Assess. Health Care 25, 391–399 (2009)CrossRefPubMed Willems, D.C.M., Joore, M.A., Nieman, F.H.M., Severens, J.L., Wouters, E.F.M., Hendriks, J.J.E.: Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. Int. J. Technol. Assess. Health Care 25, 391–399 (2009)CrossRefPubMed
29.
Zurück zum Zitat Willems, D.C.M., Joore, M.A., Hendriks, J.J.E., Wouters, E.F.M., Severens, J.L.: Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff. Resour. Alloc. CE. 5, 10 (2007)CrossRef Willems, D.C.M., Joore, M.A., Hendriks, J.J.E., Wouters, E.F.M., Severens, J.L.: Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff. Resour. Alloc. CE. 5, 10 (2007)CrossRef
30.
Zurück zum Zitat Secnik, K., Matza, L.S., Cottrell, S., Edgell, E., Tilden, D., Mannix, S.: Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 25, 56–70 (2005)CrossRef Secnik, K., Matza, L.S., Cottrell, S., Edgell, E., Tilden, D., Mannix, S.: Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 25, 56–70 (2005)CrossRef
31.
Zurück zum Zitat Matza, L.S., Secnik, K., Mannix, S., Sallee, F.R.: Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK. PharmacoEconomics. 23, 777–790 (2005)CrossRefPubMed Matza, L.S., Secnik, K., Mannix, S., Sallee, F.R.: Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK. PharmacoEconomics. 23, 777–790 (2005)CrossRefPubMed
Metadaten
Titel
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
verfasst von
Karine Chevreul
Morgane Michel
Karen Berg Brigham
Julio López-Bastida
Renata Linertová
Juan Oliva-Moreno
Pedro Serrano-Aguilar
Manuel Posada-de-la-Paz
Domenica Taruscio
Arrigo Schieppati
Georgi Iskrov
Márta Péntek
Johann Matthias Graf von der Schulenburg
Panos Kanavos
Ulf Persson
Giovani Fattore
BURQOL-RD Research Network
Publikationsdatum
08.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe Sonderheft 1/2016
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-016-0781-6

Weitere Artikel der Sonderheft 1/2016

The European Journal of Health Economics 1/2016 Zur Ausgabe